創傷ケア用生物製剤の市場規模、シェア、成長分析：製品別、傷の種類別、エンドユーザー別、地域別 - 産業予測 2025年～2032年

創傷ケア用生物製剤の世界市場規模は2023年に17億9,000万米ドルと評価され、2024年の18億8,000万米ドルから2032年には28億2,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは5.2％で成長する見通しです。

世界の創傷ケア用生物製剤市場は、ヘルスケア技術の進歩や革新的な治療ソリューションに対する需要の高まりに後押しされ、力強い成長軌道に乗っています。成長因子や幹細胞のような生物学的物質を含むこれらの製品は、慢性創傷、糖尿病性足潰瘍、熱傷に効果的に対処するため、ヘルスケア現場で支持を集めています。その要因としては、慢性疾患の罹患率の上昇や、傷の治りが遅い高齢者層の増加が挙げられます。個別化医療や先進医療への動向、入院期間や医療費を最小限に抑える努力も、この傾向をさらに後押ししています。しかし、高コスト、厳しい規制、ヘルスケア専門家の限られた認識といった課題が市場拡大を阻害し、創傷ケア用生物製剤の普及に向けたハードルとなる可能性があります。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ

創傷ケア用生物製剤市場規模：製品別& CAGR（2025-2032）

• 市場概要
• 生物学的皮膚代替品
  • ヒトドナー組織由来製品
  • 無細胞動物由来製品
  • 生合成製品
• 外用剤

創傷ケア用生物製剤市場規模：傷の種類別& CAGR（2025-2032）

• 市場概要
• 潰瘍
  • 糖尿病性足潰瘍
  • 静脈性潰瘍
  • 褥瘡
  • その他の潰瘍
• 外科的創傷および外傷
• バーンズ

創傷ケア用生物製剤市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院
• 外来手術センター
• 火傷治療センターと創傷治療クリニック

創傷ケア用生物製剤市場規模& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Smith & Nephew（United Kingdom）
• Integra LifeSciences（United States）
• Organogenesis Holdings Inc.（United States）
• MiMedx Group, Inc.（United States）
• Osiris Therapeutics, Inc.（United States）
• Aroa Biosurgery（New Zealand）
• Avita Medical（Australia）
• Derma Sciences, Inc.（United States）
• Alliqua BioMedical, Inc.（United States）
• Amnio Technology, LLC（United States）
• Tissue Regenix Group plc（United Kingdom）
• CollPlant Biotechnologies Ltd.（Israel）
• RenovaCare, Inc.（United States）
• PolarityTE, Inc.（United States）
• Cytori Therapeutics, Inc.（United States）
• Histogenics Corporation（United States）
• Vericel Corporation（United States）
• RepliCel Life Sciences Inc.（Canada）

結論と推奨事項

Global Wound Care Biologics Market size was valued at USD 1.79 billion in 2023 and is poised to grow from USD 1.88 billion in 2024 to USD 2.82 billion by 2032, growing at a CAGR of 5.2% during the forecast period (2025-2032).

The global wound care biologics market is on a robust growth trajectory, fueled by advancements in healthcare technology and increasing demand for innovative healing solutions. Comprising biological substances like growth factors and stem cells, these products effectively address chronic wounds, diabetic foot ulcers, and burns, thereby gaining traction in healthcare settings. Contributing factors include the rising incidence of chronic ailments and a growing elderly demographic vulnerable to slow-healing wounds. The movement towards personalized medicine and advanced therapies, as well as efforts to minimize hospital stays and healthcare costs, further support this trend. However, challenges such as high costs, stringent regulations, and limited awareness among healthcare professionals may inhibit market expansion, creating hurdles for widespread adoption of wound care biologics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Wound Care Biologics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Wound Care Biologics Market Segments Analysis

Global Wound Care Biologics Market is segmented by Product, Wound Type, End User and region. Based on Product, the market is segmented into Biological Skin Substitutes and Topical Agents. Based on Wound Type, the market is segmented into Ulcers, Surgical & Traumatic Wounds and Burns. Based on End User, the market is segmented into Hospitals, Ambulatory Surgery Centers and Burn Care Centers & Wound Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Wound Care Biologics Market

The global wound care biologics market is significantly propelled by the rising prevalence of chronic wounds, particularly diabetic foot ulcers and pressure ulcers. These conditions create a growing demand for innovative treatment solutions. Biologic wound care products provide exceptional therapeutic alternatives that enhance the healing process for difficult cases, making them increasingly vital in modern wound management. As healthcare professionals seek effective ways to address these complex ailments, the need for advanced biologics becomes more pronounced, driving the market's expansion. This trend underscores the critical role of biologics in improving patient outcomes in wound care settings.

Restraints in the Global Wound Care Biologics Market

The Global Wound Care Biologics market faces significant restraints due to the stringent regulatory approval processes associated with biologic wound care products. These rigorous protocols can prolong the time it takes for new products to enter the market, which not only hampers timely access for healthcare providers and patients but also escalates the overall development costs for manufacturers. As companies navigate through comprehensive testing and compliance requirements, the financial burden and extended timelines can deter innovation and the introduction of potentially beneficial solutions, ultimately impacting the growth and dynamics of the market.

Market Trends of the Global Wound Care Biologics Market

The Global Wound Care Biologics market is experiencing a significant trend towards personalized medicine, reflecting a broader healthcare shift in which treatments are customized to meet individual patient needs and specific wound characteristics. This tailored approach enhances treatment efficacy, as wound care biologics-such as growth factors, collagen-based products, and stem cell therapies-offer targeted healing solutions that address unique patient profiles. The rising prevalence of chronic wounds and advancements in biologic technologies further drive this market trend, pushing for innovations that integrate personalized strategies into standard wound care practices, thus improving patient outcomes and fostering competitive differentiation among market players.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Wound Care Biologics Market Size by Product & CAGR (2025-2032)

• Market Overview
• Biological Skin Substitutes
  • Human Donor Tissue-derived Products
  • Acellular Animal-derived Products
  • Biosynthetic Products
• Topical Agents

Global Wound Care Biologics Market Size by Wound Type & CAGR (2025-2032)

• Market Overview
• Ulcers
  • Diabetic Foot Ulcers
  • Venous Ulcers
  • Pressure Ulcers
  • Other Ulcers
• Surgical & Traumatic Wounds
• Burns

Global Wound Care Biologics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Ambulatory Surgery Centers
• Burn Care Centers & Wound Clinics

Global Wound Care Biologics Market Size & CAGR (2025-2032)

• North America (Product, Wound Type, End User)
  • US
  • Canada
• Europe (Product, Wound Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Wound Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Wound Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Wound Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Smith & Nephew (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Integra LifeSciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Organogenesis Holdings Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MiMedx Group, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Osiris Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aroa Biosurgery (New Zealand)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Avita Medical (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Derma Sciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alliqua BioMedical, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amnio Technology, LLC (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tissue Regenix Group plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CollPlant Biotechnologies Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RenovaCare, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PolarityTE, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cytori Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Histogenics Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vericel Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RepliCel Life Sciences Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations